Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Watts JM, Pollyea DA, Fathi AT, Tallman MS, Kantarjian HM, Stone RM, Quek L, Konteatis Z, Dang L, Nicolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Attar EC, Wu B. Choe S, et al. Among authors: attar ec. Blood Adv. 2020 May 12;4(9):1894-1905. doi: 10.1182/bloodadvances.2020001503. Blood Adv. 2020. PMID: 32380538 Free PMC article.
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC. Attar EC, et al. Clin Cancer Res. 2008 Mar 1;14(5):1446-54. doi: 10.1158/1078-0432.CCR-07-4626. Clin Cancer Res. 2008. PMID: 18316568 Clinical Trial.
Myelodysplastic syndromes.
Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P; NCCN Myelodysplastic Syndromes Panel. Greenberg PL, et al. J Natl Compr Canc Netw. 2008 Oct;6(9):902-26. J Natl Compr Canc Netw. 2008. PMID: 18926100 No abstract available.
Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.
Singh H, Werner LL, Asali S, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Wolpin B, Pidala J, Neuberg DS, Fox EA, Stone RM, Attar EC. Singh H, et al. Among authors: attar ec. Am J Hematol. 2011 Jul;86(7):625-7. doi: 10.1002/ajh.22041. Am J Hematol. 2011. PMID: 21681787 Free PMC article.
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
Singh H, Asali S, Werner LL, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Neuberg DS, Fox EA, Stone RM, Attar EC. Singh H, et al. Among authors: attar ec. Leuk Res. 2011 Dec;35(12):1611-5. doi: 10.1016/j.leukres.2011.05.032. Epub 2011 Jun 21. Leuk Res. 2011. PMID: 21696826 Free PMC article.
Get out--and stay out.
Attar EC. Attar EC. Blood. 2012 Apr 26;119(17):3869-70. doi: 10.1182/blood-2012-02-410357. Blood. 2012. PMID: 22538491 Free article.
NCCN Clinical Practice Guidelines Acute myeloid leukemia.
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM. O'Donnell MR, et al. J Natl Compr Canc Netw. 2012 Aug;10(8):984-1021. doi: 10.6004/jnccn.2012.0103. J Natl Compr Canc Netw. 2012. PMID: 22878824
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Fathi AT, et al. Among authors: attar ec. Blood. 2012 Nov 29;120(23):4649-52. doi: 10.1182/blood-2012-06-438267. Epub 2012 Oct 16. Blood. 2012. PMID: 23074281 Free article.
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Attar EC, et al. J Clin Oncol. 2013 Mar 1;31(7):923-9. doi: 10.1200/JCO.2012.45.2177. Epub 2012 Nov 5. J Clin Oncol. 2013. PMID: 23129738 Free PMC article. Clinical Trial.
91 results